A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia

Ayodhia Pitaloka Pasaribu, Watcharee Chokejindachai, Chukiat Sirivichayakul, Naowarat Tanomsing, Irwin Chavez, Emiliana Tjitra, Syahril Pasaribu, Mallika Imwong, Nicholas J White, Arjen M Dondorp, Ayodhia Pitaloka Pasaribu, Watcharee Chokejindachai, Chukiat Sirivichayakul, Naowarat Tanomsing, Irwin Chavez, Emiliana Tjitra, Syahril Pasaribu, Mallika Imwong, Nicholas J White, Arjen M Dondorp

Abstract

Background: A high prevalence of chloroquine-resistant Plasmodium vivax in Indonesia has shifted first-line treatment to artemisinin-based combination therapies, combined with primaquine (PQ) for radical cure. Which combination is most effective and safe remains to be established.

Methods: We conducted a prospective open-label randomized comparison of 14 days of PQ (0.25 mg base/kg) plus either artesunate-amodiaquine (AAQ + PQ) or dihydroartemisinin-piperaquine (DHP + PQ) for the treatment of uncomplicated monoinfection P. vivax malaria in North Sumatera, Indonesia. Patients were randomized and treatments were given without prior testing for G6PD status. The primary outcome was parasitological failure at day 42. Patients were followed up to 1 year.

Results: Between December 2010 and April 2012, 331 patients were included. After treatment with AAQ + PQ, recurrent infection occurred in 0 of 167 patients within 42 days and in 15 of 130 (11.5%; 95% confidence interval [CI], 6.6%-18.3%) within a year. With DHP + PQ, this was 1 of 164 (0.6%; 95% CI, 0.01%-3.4%) and 13 of 143 (9.1%; 95% CI, 4.9%-15.0%), respectively (P > .2). Intravascular hemolysis occurred in 5 patients, of which 3 males were hemizygous for the G6PD-Mahidol mutation. Minor adverse events were more frequent with AAQ + PQ.

Conclusions: In North Sumatera, Indonesia, AAQ and DHP, both combined with PQ, were effective for blood-stage parasite clearance of uncomplicated P. vivax malaria. Both treatments were safe, but DHP + PQ was better tolerated.

Clinical trials registration: NCT01288820.

Keywords: Indonesia; Plasmodium vivax; primaquine; radical cure.

Figures

Figure 1.
Figure 1.
Study flowchart. Abbreviations: P.f., Plasmodium falciparum; SAE, severe adverse event.
Figure 2.
Figure 2.
Kaplan–Meier survival efficacy analysis of all randomized patients. Abbreviations: AAQ + PQ, artesunate-amodiaquine plus primaquine; CI, confidence interval; DHP + PQ, dihydroartemisinin-piperaquine plus primaquine.
Figure 3.
Figure 3.
Kaplan–Meier analysis for recurrent infection during the 1-year follow-up period. Abbreviations: AAQ + PQ, artesunate-amodiaquine plus primaquine; DHP + PQ, dihydroartemisinin-piperaquine plus primaquine.

References

    1. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. Trends Parasitol. 2006;22:353–8.
    1. Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007;9:39–46.
    1. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva, Switzerland: WHO; 2010.
    1. Alving AS, Arnold J, Hockwald RS, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955;46:301–6.
    1. Matsuoka H, Ishii A, Panjaitan W, Sudiranto R. Malaria and glucose-6-phosphate dehydrogenase deficiency in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health. 1986;17:530–6.
    1. Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, Baird JK. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J. 2010;9:52.
    1. Baird JK, Sustriayu Nalim MF, Basri H, et al. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg. 1996;90:409–11.
    1. Sumawinata IW, Bernadeta, Leksana B, et al. Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003;68:416–20.
    1. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010;10:405–16.
    1. DitJen PPL DepKes RI. Gebrak Malaria: Pedoman Penatalaksanaan Kasus Malaria di Indonesia. Jakarta, Indonesia: Ministry of Health, 2008.
    1. Nuchprayoon I, Sanpavat S, Nuchprayoon S. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871G>A) is the most common deficiency variant in the Thai population. Hum Mutat. 2002;19:185.
    1. World Health Organization. Geneva, Switzerland: WHO; 2003. Malaria assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria.
    1. Buchachart K, Krudsood S, Singhasivanon P, et al. Southeast Asian J Trop Med Public Health. 2001;32:720–6.
    1. Moiz B, Nasir A, Moatter T, Naqvi ZA, Khurshid M. Population study of 1311 C/T polymorphism of glucose 6 phosphate dehydrogenase gene in Pakistan—an analysis of 715 X-chromosomes. BMC Genet. 2009;10:41.
    1. Beutler E, Kuhl W. The NT 1311 polymorphism of G6PD: G6PD Mediterranean mutation may have originated independently in Europe and Asia. Am J Hum Genet. 1990;47:1008–12.
    1. Louicharoen C, Patin E, Paul R, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science. 2009;326:1546–9.
    1. Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007;4:e66.
    1. Powell RD, Brewer GJ. Glucose-6-phosphate dehydrogenase deficiency and falciparum malaria. Am J Trop Med Hyg. 1965;14:358–62.
    1. Imwong M, Snounou G, Pukrittayakamee S, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195:927–33.
    1. Sutanto I, Tjahjono B, Basri H, et al. Randomized, open label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother. 2013;57:1128–35.
    1. Navaratnam V, Ramanathan S, Wahab MS, et al. Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur J Clin Pharmacol. 2009;65:809–21.
    1. Tarning J, Lindegardh N, Annerberg A, et al. Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother. 2005;49:5127–8.
    1. Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007;44:1067–74.
    1. Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis. 2010;10:673–81.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren